-
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13 Jan 2026 14:28 GMT
… , 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB … , Chief Executive Officer of XTL Biopharmaceuticals: "We are extremely excited … commercial-stage medical device and biopharmaceutical company dedicated to harnessing the …
-
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13 Jan 2026 12:30 GMT
… , 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB … , Chief Executive Officer of XTL Biopharmaceuticals: "We are extremely excited … commercial-stage medical device and biopharmaceutical company dedicated to harnessing the …
-
Sino Biopharmaceutical to buy Hygieia for up to $172M
13 Jan 2026 11:43 GMT
Hong Kong-listed Sino Biopharmaceutical said on Tuesday that it … become a subsidiary of Sino Biopharmaceutical.
The acquisition marks the latest … step in Sino Biopharmaceutical’s expansion strategy aimed at …
-
Sino Biopharmaceutical buys drugmaker Hangzhou Hygieia Biomedical for up to $172 million
13 Jan 2026 10:50 GMT
… - Hong Kong-listed Sino Biopharmaceutical said on Tuesday it … chronic-disease treatments. Sino Biopharmaceutical said a unit would … become a unit of Sino Biopharmaceutical, it added. The … deal marks Sino Biopharmaceutical';s latest acquisition, …
-
NeuroScientific Biopharmaceuticals soars on stem cell tech results
13 Jan 2026 03:10 GMT
… ’s exactly what NeuroScientific Biopharmaceuticals appears to have delivered, … StemSmart moving forward.
NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith …
NeuroScientific Biopharmaceuticals chief medical officer Dr …
-
New GTPase KRAS inhibitors disclosed in SK Biopharmaceuticals patent
12 Jan 2026 17:10 GMT
-
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
12 Jan 2026 15:15 GMT
… to $0.89.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) gained 24 …
-
Angitia Biopharmaceuticals Announces Dosing of First Participant in Phase 2 IDUN Trial of AGA2115 for the Treatment of Osteogenesis Imperfecta
12 Jan 2026 12:30 GMT
… 2026 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company … with OI. About Angitia Biopharmaceuticals Angitia Biopharmaceuticals is a clinical-stage … release is prepared by Angitia Biopharmaceuticals (the “Company”, “We”) for …
-
SK Biopharmaceuticals Wins FDA Approval for Phase 1 Trial of Alpha-emitter RPT Drug
12 Jan 2026 08:38 GMT
… radiopharmaceutical therapy (RPT) field. SK Biopharmaceuticals said it plans to target … an effective dosage range, SK Biopharmaceuticals will transition into dose optimization … combines therapy and diagnostics.
SK Biopharmaceuticals first entered the RPT field …
-
FDA clears SK biopharmaceuticals to begin phase 1 radiopharmaceutical trial
12 Jan 2026 07:10 GMT
… -emitter program, making SK biopharmaceuticals the first Korean company to … tumor uptake during therapy.
SK biopharmaceuticals entered the radiopharmaceutical field in … development in radiopharmaceutical therapy,” SK biopharmaceuticals CEO Lee Dong-hoon said …
About
© 1995-2026